Specialty Platforms
Advanced Modality Chemistry
Deep chemistry expertise in the complex modalities driving the next generation of drug discovery — PROTACs, ADCs, Peptides, and Macrocycles.
PROTAC, ADC, Peptide, Macrocycle
Deep chemistry expertise in the complex modalities driving the next generation of drug discovery — PROTACs, ADCs, Peptides, and Macrocycles.
Targeted protein degradation is one of the most exciting frontiers in drug discovery. Astinova brings specialized synthetic expertise to the demanding chemistry required to design and synthesize effective PROTAC and molecular glue degraders.
PROTACs are hetero-bifunctional molecules requiring precise coupling of a target-binding warhead, a carefully designed linker, and an E3 ligase-recruiting ligand — often via 10–20+ step synthesis routes with multiple stereocenters and sensitive functional groups.
Antibody-drug conjugates (ADCs) and degrader-antibody conjugates (DACs) depend critically on the quality and design of their small molecule components — the linkers and cytotoxic payloads that define efficacy and safety.
Astinova synthesizes high-purity ADC components, including cleavable and non-cleavable linkers, cytotoxic payload analogs, and complete linker-payload constructs ready for bioconjugation.
Key differentiator: We synthesize complete linker-payload conjugates (not just payloads alone), enabling streamlined antibody conjugation by your bioconjugation team.
Peptide-based therapeutics — including cyclic peptides, stapled peptides, and cell-penetrating peptides — require specialized synthetic expertise beyond standard Fmoc SPPS. We provide advanced key starting materials, custom building blocks, and challenging sequence synthesis.
For oligonucleotide programs, we synthesize modified nucleotides and phosphoramidite building blocks with the chemical precision required for antisense, siRNA, and aptamer applications.
Macrocyclic drugs occupy a unique chemical space between small molecules and biologics, offering excellent selectivity and the ability to hit previously undruggable targets. Their synthesis demands mastery of macrocyclization chemistry and stereocontrol.
Astinova's synthetic team has deep experience in asymmetric synthesis, including multi-chiral center control, enantioselective reactions, and atroposelective synthesis for atropisomeric drug candidates.
Highlight capability: Atroposelective synthesis of axially chiral biaryl compounds — increasingly important in modern kinase inhibitor and PROTAC programs.
Our chemistry experts are ready to discuss your program needs and propose a tailored approach.